Guardant Health (GH) PT Raised to $40 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
August 7, 2024 4:05 PM EDTRevenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds
Shield approved by FDA as primary option for CRC screening and is commercially available in U.S.
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2024.
Second Quarter 2024 Financial Highlights
Revenue of $177.2 million for the second quarter of 2024, an increase of 29% over the second quarter of 2023 Reported 49,400 tests to... MoreGuardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
August 7, 2024 8:05 AM EDTLargest study to date evaluating MRD detection using tissue-free approach demonstrates 81% longitudinal sensitivity for recurrence in stage II or higher colon cancer Data demonstrate potential clinical utility of ctDNA as tool to improve management of stage II and higher CRC that allows for rapid evaluation without complexity of prior tissue analysis
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Clinical Cancer Research, a journal of the American Association for Cancer Research, will publish... More
